Effect of Statins, Metformin, Angiotensin-Converting Enzyme Inhibitors, and Angiotensin II Receptor Blockers on Age-Related Macular Degeneration

Figures

• 

  Fig. 1. Flowchart of study cohort construction. *Cohort entry date was matched with the cohort entry date of the cases, ranging from 30 days before or after the entry date.

• 

  Fig. 2. Subgroup analyses of the associations between AMD and exposures according to the type of AMD and presence of cerebrovascular diseases. *Adjusted for income level, Charlson comorbidity index, the number of prescriptions, cerebrovascular disease history, complicated or uncomplicated diabetes, hyperlipidemia, hypertension and peripheral vascular disease, and the use of alpha-blockers, alpha-glucosidase, aspirin, beta-blockers, calcium channel blockers, diuretics, meglitinide, sulfonylurea, or thiazolidinedione. AMD, age-related macular degeneration; ACE inhibitors, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor blockers; aORs, adjusted odds ratios; CI, confidence interval.